Socazolimab
Socazolimab is Lee's Pharmaceutical's PD-L1 antibody, in phase 3 trials in China for extensive-stage small cell lung cancer and recurrent cervical cancer.
Overview
Socazolimab (ZKAB001), licensed by Lee's Pharmaceutical from Sorrento, is a fully human PD-L1 antibody. Its phase 3 programme in China includes first-line extensive-stage small cell lung cancer with chemotherapy and recurrent or metastatic cervical cancer; earlier trials included osteosarcoma. OnCo records its Chinese regulatory status only where a source states it.
Binds PD-L1 on tumour and immune cells so it cannot engage PD-1 on T cells. Connects to PD-L1.
1.Socazolimab binds PD-L1.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Socazolimab" OR ABSTRACT:"Socazolimab" OR TITLE:"ZKAB001" OR ABSTRACT:"ZKAB001") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Socazolimab, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentRetlirafusp alfa
Shares PD-L1, Immune checkpoint inhibitors and the tag pipeline.
- TreatmentSSGJ-706
Shares PD-L1 and the tag pipeline.
- TreatmentHB0036
Shares PD-L1 and the tag pipeline.
- TreatmentHLX43
Shares PD-L1, Cervical cancer and the tag pipeline.
- TreatmentSasanlimab
Shares PD-L1 and the tag pipeline.
- TreatmentPF-08046054
Shares PD-L1 and the tag pipeline.
- TreatmentZimberelimab
Shares Cervical cancer, Immune checkpoint inhibitors and the tag pipeline.
- TreatmentAcasunlimab
Shares PD-L1 and the tag pipeline.